Advisor Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $2.85M | Buy |
10,133
+1,403
| +16% | +$376K | 0.2% | 99 |
|
|
2022
Q1 | $2.28M | Buy |
8,730
+2,678
| +44% | +$636K | 0.14% | 143 |
|
|
2021
Q4 | $1.33M | Buy |
6,052
+1,213
| +25% | +$236K | 0.08% | 241 |
|
|
2021
Q3 | $878K | Sell |
4,839
-650
| -12% | -$127K | 0.06% | 304 |
|
|
2021
Q2 | $1.11M | Sell |
5,489
-924
| -14% | -$193K | 0.07% | 264 |
|
|
2021
Q1 | $1.38M | Sell |
6,413
-465
| -7% | -$102K | 0.1% | 202 |
|
|
2020
Q4 | $1.63M | Sell |
6,878
-731
| -10% | -$168K | 0.12% | 162 |
|
|
2020
Q3 | $2.07M | Sell |
7,609
-201
| -3% | -$55.5K | 0.18% | 109 |
|
|
2020
Q2 | $2.27M | Buy |
7,810
+623
| +9% | +$169K | 0.21% | 93 |
|
|
2020
Q1 | $1.71M | Buy |
7,187
+1,215
| +20% | +$279K | 0.21% | 106 |
|
|
2019
Q4 | $1.4M | Buy |
5,972
+332
| +6% | +$67.2K | 0.14% | 141 |
|
|
2019
Q3 | $956K | Buy |
5,640
+225
| +4% | +$39.8K | 0.12% | 187 |
|
|
2019
Q2 | $993K | Sell |
5,415
-450
| -8% | -$78.7K | 0.12% | 172 |
|
|
2019
Q1 | $1.08M | Buy |
5,865
+4
| +0.1% | +$739 | 0.14% | 150 |
|
|
2018
Q4 | $971K | Buy |
5,861
+795
| +16% | +$138K | 0.16% | 142 |
|
|
2018
Q3 | $976K | Sell |
5,066
-14
| -0.3% | -$2.49K | 0.13% | 158 |
|
|
2018
Q2 | $863K | Buy |
5,080
+23
| +0.5% | +$3.56K | 0.15% | 160 |
|
|
2018
Q1 | $824K | Buy |
5,057
+58
| +1% | +$9.47K | 0.15% | 149 |
|
|
2017
Q4 | $790K | Sell |
4,999
-52
| -1% | -$7.7K | 0.14% | 161 |
|
|
2017
Q3 | $768K | Buy |
5,051
+26
| +0.5% | +$3.91K | 0.15% | 146 |
|
|
2017
Q2 | $648K | Buy |
5,025
+860
| +21% | +$104K | 0.15% | 164 |
|
|
2017
Q1 | $455K | Buy |
4,165
+981
| +31% | +$86.4K | 0.12% | 212 |
|
|
2016
Q4 | $235K | Buy |
3,184
+146
| +5% | +$11.9K | 0.07% | 343 |
|
|
2016
Q3 | $265K | Buy |
3,038
+170
| +6% | +$16.1K | 0.09% | 289 |
|
|
2016
Q2 | $247K | Buy |
+2,868
| New | +$248K | 0.09% | 281 |
|
|
2016
Q1 | – | Sell |
-2,735
| Closed | -$344K | – | 417 |
|
|
2015
Q4 | $344K | Sell |
2,735
-101
| -4% | -$12.2K | 0.12% | 183 |
|
|
2015
Q3 | $295K | Buy |
2,836
+147
| +5% | +$18.9K | 0.12% | 199 |
|
|
2015
Q2 | $319K | Buy |
2,689
+246
| +10% | +$31K | 0.12% | 213 |
|
|
2015
Q1 | $288K | Buy |
2,443
+71
| +3% | +$8.51K | 0.12% | 224 |
|
|
2014
Q4 | $282K | Buy |
2,372
+357
| +18% | +$40.2K | 0.12% | 216 |
|
|
2014
Q3 | $226K | Buy |
+2,015
| New | +$192K | 0.13% | 203 |
|
Other funds holding VRTX
Advisor Partners's VRTX Position: Q2 2022 in Review
Advisor Partners increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2022, buying an estimated $376K and bringing the position to 10,133 shares worth $2.85M. The position accounts for 0.2% of the portfolio, ranked #99.
Advisor Partners first reported a position in VRTX in Q3 2014 and has held it in 31 quarters since. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.
- Advisor Partners held 10,133 shares of Vertex Pharmaceuticals worth $2.85M as of Q2 2022.
- Advisor Partners bought 1,403 Vertex Pharmaceuticals shares in Q2 2022, an estimated $376K.
- Vertex Pharmaceuticals made up 0.2% of Advisor Partners's portfolio in Q2 2022, its #99 holding.
- Advisor Partners first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 31 quarters since.
- 1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.